Please login to the form below
FujiFilm
This page shows the latest FujiFilm news and features for those working in and with pharma, biotech and healthcare.
Novavax is close to finalising a COVID-19 vaccine supply deal with the EU
To support roll-out in the UK, Novavax partnered with FUJIFILM Diosynth Biotechnologies to manufacture certain components of the vaccine in the UK, including the protein antigen component.
Latest news
-
GSK to assist in manufacturing up to 60 million doses of Novavax’s COVID-19 vaccine in the UK
Novavax also partnered with FUJIFILM Diosynth Biotechnologies to manufacture certain components of the vaccine in the UK, including the protein antigen component.
-
UK trial of Novavax COVID-19 vaccine demonstrates 89.3% efficacy
Novavax also partnered with FUJIFILM Diosynth Biotechnologies to manufacture certain components of the vaccine in the UK.
-
Novavax moves closer toward launch of US phase 3 COVID-19 vaccine trial
study. Novavax is planning to use vaccine material produced at a FUJIFILM Diosynth Biotechnologies plant in North Carolina to support the commercial scale-up required for phase 3 trials in the
-
Novavax starts first phase 3 COVID-19 vaccine trial in the UK
The UK government also signed a deal with Novavax in August, which led to the phase 3 clinical trial, and has also partnered with FUJIFILM Diosynth Biotechnologies to manufacture certain components
-
UK agrees on COVID-19 vaccine deals with J&J and Novavax
Novavax will also conduct a phase 3 clinical trial of its vaccine candidate with support from the UK’s National Institute for Health Research (NIHR), and has partnered with FUJIFILM Diosynth
More from news
Approximately 2 fully matching, plus 12 partially matching documents found.
Latest Intelligence
-
Deal Watch March 2016
The sale of the diagnostic imaging business was believed to be hotly contested by Fujifilm and Konica Minolta, with Canon the successful bidder.
-
Pharma deals in July 2015
Still in Japan, a week later AZ agreed a joint venture with Fujifilm Kyowa Kirin Biologics for the development and commercialisation of a biosimilar version of bevacizumab (Avastin) in phase I ... Fujifilm Kyowa KirinBiologics will transfer the product
-
Pharma deals in March 2015
The high level of interest in cell therapies generally may have been one reason why Fujifilm acquired Cellular Dynamics for $307m at an eye watering share price premium of 108%. ... Fujifilm expects to achieve significant synergies. Checkpoint inhibitors
More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.
Latest appointments
-
BIA elects six new board members
The remaining new appointments are Stephen Taylor of Fujifilm Diosynth Biotechnologies; Donna Hackett, director of life sciences consultancy firm KDH BioManagement; and Tim Watts, chief financial officer of Oxford BioMedica.
More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- FREELANCE Associate Director - Healthcare PR - Remote or London
-
Superb Day Rate &Benefits
- Principal Medical Writer, MRNA/ Covid 19, Medical Communications...
-
Highly competitive salary
- Client Services Director, MRNA/ Covid 19, Medical Communications...
-
Highly competitive salary
- Scientific Director, MRNA/ Covid 19, Medical Communications, UK
-
Six figure salary
- Vaccines writer – career opportunity to move into medcomms from ...
-
Highly competitive salary
-
B2B media account director
-
Competitive salary
- Senior Account Exec > CSD – Medical Communications – UK, Lond...
-
Highly Competitive Salary, Bonus &Benefits
- Medical Writers > Scientific Directors – Medical Communicatio...
-
Highly Competitive Salary, Bonus &Benefits
- AM / Senior Account Manager – Healthcare PR - London / Remote
-
Highly Competitive Salary, Bonus &Benefits
- Omicron rise prompts tougher measures in England
- Pfizer/BioNTech promote booster against Omicron
- What is EVID AI?
- Virtual meeting technologies for reducing emissions and waste in the healthcare industry
- AstraZeneca and Ionis sign $3.6bn deal for eplontersen
- Roche’s Actemra approved for severe COVID-19 in Europe
- Results for Merck’s oral cholesterol inhibitor show it to be ‘highly effective’
- Sanofi to buy acne specialist Origimm
- Gilead’s Trodelvy approved for triple-negative breast cancer in Europe
- Promoting off-label use: where to draw the line?
- Synairgen’s SNG001 advances into phase 3 COVID-19 trial
- Engaging HCPs on their own terms: how pharma can adapt to the post-pandemic digital era
PMHub
Origins Insights
Our goal is to identify and embed transformational patient insights as a fundamental part of the drug development process. As...
Latest intelligence
- Virtual meeting technologies for reducing emissions and waste in the healthcare industry
- ...
- Diversity in clinical trials: looking back at our 2021 blogs
- In this blog, we look back at the Innovative Trials' Equality & Diversity (E&D) committee blogs across 2021...
- What does the future hold for Light-chain Amyloidosis?
- Recent advances in the understanding and treatment are reforming pharma’s approach to the management of this rare disease. With a new standard of care rapidly developing, what does the landscape...
